• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症治疗-肾症状指数功能性评估量表(FKSI-19)在肾细胞癌患者中的心理测量学评估提示其存在一种替代的两因素结构。

A psychometric evaluation of the Functional assessment of cancer therapy-kidney symptom index (FKSI-19) among renal cell carcinoma patients suggesting an alternative two-factor structure.

机构信息

Regional Cancer Centre Stockholm-Gotland, Region Stockholm, Box 6909, SE-102 39, Stockholm, Sweden.

Department of Medical Sciences, Division of Clinical Diabetology and Metabolism, Uppsala University, Uppsala, Sweden.

出版信息

Qual Life Res. 2021 Sep;30(9):2663-2670. doi: 10.1007/s11136-021-02839-9. Epub 2021 Apr 12.

DOI:10.1007/s11136-021-02839-9
PMID:33846957
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8405510/
Abstract

PURPOSE

To psychometrically evaluate the hypothesized four-factor structure of the 19-item Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-19) health-related quality of life (HRQoL) instrument in a sample of surgically treated renal cell carcinoma (RCC) patients and examine if an alternative factor structure with good psychometric properties may be derived from the available items.

METHODS

The model fit of the hypothesized four-factor structure was examined using confirmatory factor analysis on cohort data from 1731 individuals included in the National Swedish Kidney Cancer Register who had undergone surgery for RCC during the three years 2016-2018 and answered the FKSI-19 instrument within 6-12 months after surgery. Exploratory factor analysis was applied to the same dataset to derive a possible alternative factor solution.

RESULTS

The four-factor structure did not reach the thresholds for good model fit using the normed χ-value or the Comparative Fit Index, although the Standardized Root Mean Square Residual and Root Mean Square Error of Approximation measures indicated good and acceptable model fits, respectively. An alternative 14-item trimmed FKSI version (FKSI-14) with a two-factor structure derived from the available FKSI-19 items was found to measure the same aspects of HRQoL as the full FKSI-19 instrument.

CONCLUSION

The present study is the first to use psychometric methods for examining the factor structure of the FKSI-19 instrument. The hypothesized four-factor structure of FKSI-19 provided a barely acceptable model fit. The two-factor FKSI-14 structure may be used as an alternative or complement to the four-factor structure when interpreting the FKSI-19 instrument.

摘要

目的

在接受手术治疗的肾细胞癌 (RCC) 患者样本中,对假设的 19 项癌症治疗功能评估-肾脏症状指数 (FKSI-19) 健康相关生活质量 (HRQoL) 量表的 19 项进行心理测量评估,考察是否可以从现有项目中推导出具有良好心理测量特性的替代因素结构。

方法

使用来自全国瑞典肾脏癌登记处的队列数据,对假设的四因素结构进行验证性因子分析,该队列包括 1731 名在 2016-2018 年三年内接受 RCC 手术且在手术后 6-12 个月内回答 FKSI-19 量表的个体。对同一数据集进行探索性因子分析,以推导出可能的替代因素解决方案。

结果

尽管标准化均方根残差和近似误差均方根的测量值分别表示良好和可接受的模型拟合,但使用规范化 χ 值或比较拟合指数,四因素结构均未达到良好模型拟合的标准。从可用的 FKSI-19 项目中推导出具有双因素结构的 14 项简化 FKSI 版本 (FKSI-14),该版本被发现与完整的 FKSI-19 仪器一样可以衡量 HRQoL 的相同方面。

结论

本研究首次使用心理测量方法来检验 FKSI-19 仪器的因素结构。FKSI-19 的假设四因素结构提供了勉强可接受的模型拟合。当解释 FKSI-19 仪器时,FKSI-14 的两因素结构可能作为替代或补充四因素结构使用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/815f/8405510/291a884ad22c/11136_2021_2839_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/815f/8405510/291a884ad22c/11136_2021_2839_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/815f/8405510/291a884ad22c/11136_2021_2839_Fig1_HTML.jpg

相似文献

1
A psychometric evaluation of the Functional assessment of cancer therapy-kidney symptom index (FKSI-19) among renal cell carcinoma patients suggesting an alternative two-factor structure.癌症治疗-肾症状指数功能性评估量表(FKSI-19)在肾细胞癌患者中的心理测量学评估提示其存在一种替代的两因素结构。
Qual Life Res. 2021 Sep;30(9):2663-2670. doi: 10.1007/s11136-021-02839-9. Epub 2021 Apr 12.
2
A Comparison of the Renal Cell Carcinoma-Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).肾细胞癌症状指数(RCC-SI)与癌症治疗功能评估-肾脏症状指数(FKSI)的比较。
J Pain Symptom Manage. 2009 Aug;38(2):291-8. doi: 10.1016/j.jpainsymman.2008.08.013. Epub 2009 Apr 8.
3
Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).癌症治疗功能评估-肾脏症状指数(FKSI)的开发与验证
J Support Oncol. 2006 Apr;4(4):191-9.
4
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.在CheckMate 025研究中,接受纳武单抗与依维莫司治疗的晚期肾细胞癌患者的生活质量:一项随机、开放标签的3期试验。
Lancet Oncol. 2016 Jul;17(7):994-1003. doi: 10.1016/S1470-2045(16)30125-5. Epub 2016 Jun 6.
5
Using the Rasch model to validate and enhance the interpretation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index--Disease-Related Symptoms scale.使用拉施模型验证并增强对癌症治疗功能评估-肾脏症状指数-疾病相关症状量表的解释。
Value Health. 2009 Jun;12(4):580-6. doi: 10.1111/j.1524-4733.2008.00473.x. Epub 2008 Nov 11.
6
Psychometric properties of the kidney disease quality of life-36 (KDQOL-36) in Ethiopian patients undergoing hemodialysis.在接受血液透析的埃塞俄比亚患者中,肾脏病生活质量-36 问卷(KDQOL-36)的心理测量学特性。
Health Qual Life Outcomes. 2022 Feb 10;20(1):24. doi: 10.1186/s12955-022-01932-y.
7
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.索拉非尼耐药转移性肾细胞癌中基线患者报告的肾癌特异性症状作为中位生存的指标。
J Cancer Surviv. 2011 Sep;5(3):255-62. doi: 10.1007/s11764-011-0178-6. Epub 2011 Apr 7.
8
Development of a 12-item short version of the HIV stigma scale.一份包含12个条目的HIV污名量表简版的编制。
Health Qual Life Outcomes. 2017 May 30;15(1):115. doi: 10.1186/s12955-017-0691-z.
9
Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.舒尼替尼或干扰素α治疗转移性肾细胞癌患者的生活质量:一项III期随机试验的结果
J Clin Oncol. 2008 Aug 1;26(22):3763-9. doi: 10.1200/JCO.2007.13.5145.
10
Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma.转移性肾细胞癌患者的癌症治疗-肾脏症状指数疾病相关症状功能评估中的重要组间差异。
Value Health. 2018 Dec;21(12):1413-1418. doi: 10.1016/j.jval.2018.04.1371. Epub 2018 May 11.

引用本文的文献

1
Reply to Letter to the Editor about "Recurrences after nephron-sparing treatments of renal cell carcinoma: a competing risk analysis" by Qiang et al.
World J Urol. 2024 Nov 4;42(1):621. doi: 10.1007/s00345-024-05304-7.
2
Recurrences after nephron-sparing treatments of renal cell carcinoma: a competing risk analysis.肾细胞癌保留肾单位治疗后的复发:一项竞争风险分析。
World J Urol. 2024 Aug 7;42(1):474. doi: 10.1007/s00345-024-05172-1.
3
The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214.CheckMate 214 研究中晚期肾细胞癌患者健康相关生活质量与总生存期的关系

本文引用的文献

1
The renal cell cancer database Sweden (RCCBaSe) - a new register-based resource for renal cell carcinoma research.瑞典肾细胞癌数据库 (RCCBaSe) - 一个基于登记的肾细胞癌研究新资源。
Scand J Urol. 2020 Jun;54(3):235-240. doi: 10.1080/21681805.2020.1766561. Epub 2020 May 21.
2
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.欧洲泌尿外科学会肾癌指南:2019 年更新版。
Eur Urol. 2019 May;75(5):799-810. doi: 10.1016/j.eururo.2019.02.011. Epub 2019 Feb 23.
3
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Oncologist. 2024 Jun 3;29(6):511-518. doi: 10.1093/oncolo/oyae003.
4
Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19.患者对癌症治疗功能评估-肾症状指数 19 中包含项目相关性的看法。
Oncologist. 2023 Jun 2;28(6):494-500. doi: 10.1093/oncolo/oyad028.
5
A Systematic Review of Heterogeneity in Outcome Definition and Reporting in Localised Renal Cancer.局限性肾癌结局定义与报告异质性的系统评价
Eur Urol Open Sci. 2022 Dec 15;48:1-11. doi: 10.1016/j.euros.2022.11.014. eCollection 2023 Feb.
全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
4
Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma.更新的欧洲泌尿外科学会关于同步转移性透明细胞肾细胞癌患者细胞减瘤性肾切除术的指南。
Eur Urol. 2018 Dec;74(6):805-809. doi: 10.1016/j.eururo.2018.08.008. Epub 2018 Aug 31.
5
Renal cell carcinoma.肾细胞癌。
Nat Rev Dis Primers. 2017 Mar 9;3:17009. doi: 10.1038/nrdp.2017.9.
6
Impact of quality indicators on adherence to National and European guidelines for renal cell carcinoma.质量指标对肾细胞癌国家和欧洲指南依从性的影响。
Scand J Urol. 2016;50(1):2-8. doi: 10.3109/21681805.2015.1059882. Epub 2015 Jul 23.
7
Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005-2010: a population-based study from the national Swedish kidney cancer register.2005 - 2010年瑞典肾细胞癌的肿瘤特征及外科治疗:一项基于瑞典国家肾癌登记处的人群研究
Scand J Urol. 2014 Jun;48(3):231-8. doi: 10.3109/21681805.2013.864698. Epub 2014 Mar 25.
8
Development and initial validation of the NCCN/FACT symptom index for advanced kidney cancer.晚期肾癌 NCCN/FACT 症状指数的制定和初步验证。
Value Health. 2013 Jul-Aug;16(5):789-96. doi: 10.1016/j.jval.2013.04.015. Epub 2013 Jun 19.
9
Metastatic potential in renal cell carcinomas ≤7 cm: Swedish Kidney Cancer Quality Register data.直径≤7cm 肾细胞癌的转移潜能:瑞典肾癌质量登记数据。
Eur Urol. 2011 Nov;60(5):975-82. doi: 10.1016/j.eururo.2011.06.029. Epub 2011 Jul 1.
10
The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research.瑞典个人身份证号码:在医疗保健和医学研究中的可能性和陷阱。
Eur J Epidemiol. 2009;24(11):659-67. doi: 10.1007/s10654-009-9350-y. Epub 2009 Jun 6.